Search Results - Hurley, Raelene

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

    H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma by Joshi, Jaya Julie, Coffey, Heather, Corcoran, Erik, Tsai, Jennifer, Huang, Chia-Ling, Ichikawa, Kana, Prajapati, Sudeep, Hao, Ming-Hong, Bailey, Suzanna, Wu, Jeremy, Rimkunas, Victoria, Karr, Craig, Subramanian, Vanitha, Kumar, Pavan, MacKenzie, Crystal, Hurley, Raelene, Satoh, Takashi, Yu, Kun, Park, Eunice, Rioux, Nathalie, Kim, Amy, Lai, Weidong G, Yu, Lihua, Zhu, Ping, Buonamici, Silvia, Larsen, Nicholas, Fekkes, Peter, Wang, John, Warmuth, Markus, Reynolds, Dominic J, Smith, Peter G, Selvaraj, Anand

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

    Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms by Huang, Shih-Min A., Wang, Anlai, Greco, Rita, Li, Zhifang, Sun, Fangxian, Barberis, Claude, Tabart, Michel, Patel, Vinod, Schio, Laurent, Hurley, Raelene, Chen, Bo, Cheng, Hong, Lengauer, Christoph, Pollard, Jack, Watters, James, Garcia-Echeverria, Carlos, Wiederschain, Dmitri, Adrian, Francisco, Zhang, JingXin

    Published in Oncotarget
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract 3126: H3B6527, a selective and potent FGFR4 inhibitor for FGF19-driven hepatocellular carcinoma

    Abstract 3126: H3B6527, a selective and potent FGFR4 inhibitor for FGF19-driven hepatocellular carcinoma by Selvaraj, Anand, Corcoran, Erik, Coffey, Heather, Prajapati, Sudeep, Hao, Ming-Hong, Larsen, Nicholas, Tsai, Jennifer, Satoh, Takashi, Ichikawa, Kana, Joshi, Julie Jaya, Hurley, Raelene, Wu, Jeremy, Huang, Chia-Ling, Bailey, Suzanna, Karr, Craig, Kumar, Pavan, Rimkunas, Victoria, Mackenzie, Crystal, Rioux, Nathalie, Kim, Amy, Akare, Sandeep, Lai, George, Yu, Lihua, Fekkes, Peter, Wang, John, Warmuth, Markus, Smith, Peter, Reynolds, Dominic

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance

    Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance by Huang, Shih-Min A, Wang, Anlai, Greco, Rita, Li, Zhifang, Barberis, Claude, Tabart, Michel, Patel, Vinod, Schio, Laurent, Hurley, Raelene, Chen, Bo, Cheng, Hong, Lengauer, Christoph, Pollard, Jack, Watters, James, Garcia-Echeverria, Carlos, Wiederschain, Dmitri, Adrian, Francisco, Zhang, JingXin

    Published in Oncotarget
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Abstract 2435: Anticipating clinical resistance to SAR302503, a JAK2 inhibitor in clinical development for the treatment of myelofibrosis

    Abstract 2435: Anticipating clinical resistance to SAR302503, a JAK2 inhibitor in clinical development for the treatment of myelofibrosis by Hurley, Raelene, Greco, Rita, Sun, Fangxian, Wang, Anlai, Huang, Shih-Min A., Zhang, Jenny, Lebedinsky, Claudia, Cohen, Pamela, Adrian, Francisco

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models

    Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models by Greco, Rita, Hurley, Raelene, Sun, Fangxian, Yang, Lu, Yu, Qunyan, Williams, Juliet, Dorsch, Marion, Cohen, Pamela, Adrián, Francisco

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: